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Arsenic trioxide down-regulates antiapoptotic genes and induces
cell death in mycosis fungoides tumors in a mouse model
Abstract
BACKGROUND: Mycosis fungoides (MF) is the most frequent cutaneous T-cell lymphoma (CTCL).
Arsenic trioxide (As(2)O(3)) has recently been shown to be effective against leukemias, so we studied
whether As(2)O(3) induces apoptosis of CTCL cells in vitro. We further investigated if As(2)O(3) is
effective in a MF mouse model. MATERIAL AND METHODS: Annexin V/7-amino-actinomycin-D
stainings were carried out to investigate if As(2)O(3) induced apoptosis of CTCL cell lines. To study the
underlying mechanisms, the effects of As(2)O(3) on various transcription factors and apoptosis
regulating proteins were analyzed by western blots, electrophoretic mobility shift assays and
transcription factor enzyme-linked immunosorbent assays. The ability of As(2)O(3) to induce tumor
regression was investigated in a MF mouse model. RESULTS: As(2)O(3)-induced apoptosis was
paralleled by a reduction of the DNA-binding activities of transcription factors of the NFkB and signal
transducer and activator of transcription gene families and reduced expression of the antiapoptotic
proteins bcl-1, bcl-xL and mcl-1. Local injections of 200 muM As(2)O(3) into tumors caused complete
remissions in five of six mice and one partial remission. CONCLUSIONS: As(2)O(3) induced apoptosis
of CTCL cells by the down-regulation of transcription factors that stimulate the expression of
antiapoptotic genes. Local injection of As(2)O(3) into MF tumor-bearing mice resulted in tumor
regression.
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Background: Mycosis fungoides (MF) is the most frequent cutaneous T-cell lymphoma (CTCL). Arsenic trioxide
(As2O3) has recently been shown to be effective against leukemias, so we studied whether As2O3 induces apoptosis of
CTCL cells in vitro. We further investigated if As2O3 is effective in a MF mouse model.
Material and methods: Annexin V/7-amino-actinomycin-D stainings were carried out to investigate if As2O3
induced apoptosis of CTCL cell lines. To study the underlying mechanisms, the effects of As2O3 on various
transcription factors and apoptosis regulating proteins were analyzed by western blots, electrophoretic mobility shift
assays and transcription factor enzyme-linked immunosorbent assays. The ability of As2O3 to induce tumor regression
was investigated in a MF mouse model.
Results: As2O3-induced apoptosis was paralleled by a reduction of the DNA-binding activities of transcription factors
of the NFkB and signal transducer and activator of transcription gene families and reduced expression of the
antiapoptotic proteins bcl-1, bcl-xL and mcl-1. Local injections of 200 lM As2O3 into tumors caused complete
remissions in five of six mice and one partial remission.
Conclusions: As2O3 induced apoptosis of CTCL cells by the down-regulation of transcription factors that stimulate
the expression of antiapoptotic genes. Local injection of As2O3 into MF tumor-bearing mice resulted in tumor
regression.
Key words: cancer therapy, cell death/survival genes, cutaneous T-cell lymphoma, gene regulation, oncogenes,
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introduction
Cutaneous T-cell lymphomas (CTCL) are a class of non-
Hodgkin’s lymphoma and are the second most common
extranodal lymphomas, characterized by a clonal proliferation
of neoplastic T lymphocytes [1, 2]. The two main forms are
mycosis fungoides (MF), which is the most common type of
CTCL, and its leukemic form, the Se´zary syndrome (SS). MF
remains confined to the skin and often presents with patches
and plaques or in more advanced forms with tumors and
a generalized erythema (erythroderma). Most patients will only
experience skin symptoms without serious complications. In
early clinical stages, malignant T cells are present in the
epidermis, particularly along the basal layer and adjacent to
Langerhans cells. However, as disease progresses, neoplastic
cells are detected within dermal infiltrates in increasing
numbers, at times entailed with loss of epidermotropism. In
contrast, SS patients show a generalized erythroderma,
leukemic T cells in the blood and a reduced life expectancy
compared with MF patients with only 30% of patients
surviving beyond 5 years after diagnosis. This is probably due
to the circulating malignant T cells which produce various
immunosuppressing molecules such as interleukin (IL)-10,
which might lead to a down-regulation of the immunological
tumor surveillance.
There are various therapeutic modalities that show activity in
CTCL [3, 4]. MF patients in early stages are generally treated
with glucocorticoids, retinoids, extracorporal photopheresis or
more effectively with psoralen and UVA (PUVA). PUVA
therapy shows complete remission for 6–30 months in >80% of
the patients, but the patients relapse. Advanced MF stages and
SS are treated with PUVA in combination with interferon-a,
locally applied cytostatics such as 1,3-bis(2-chloroethyl)-1-
nitrosourea or radiation therapy [4, 5]. Currently, no cure for
either form of CTCL has been found.
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As mentioned above, CTCL tumors remain restricted to the
skin for most of the time as the disease progresses. The low
number of mitotic cells led to the idea that the increase of the
tumor mass is due to the overexpression of cell survival genes
such as bcl-2 which protect tumor cells from programmed
cell death (apoptosis) [6] rather than oncogenes that promote
cell growth. Indeed, it has been found that the antiapoptotic
genes bcl-2, bcl-xL and mcl-1 are expressed in CTCL cells and
that the expression levels of the latter increase with the
progression of the disease [7].
IL-7 and IL-15 are growth factors for CTCL cells that are
produced by skin keratinocytes and CTCL cells themselves
[8–11]. Both ILs stimulate the expression of bcl-2 [12]. CTCL
cells possess also constitutive NFkB, c-myb and signal
transducer and activator of transcription (STAT)5 [12–17]
activities that may stimulate the transcription of the apoptosis
inhibitors cIAP2 [17] and bcl-2. NFkB activities may
therefore also increase the survival of CTCL cells. Agents that
suppress NFkB activity and/or bcl-2 expression may be good
candidates for the treatment of CTCL, as they should be
able to induce apoptosis in CTCL cells.
Arsenic-containing compounds like As2O3 and melarsoprol
have been shown to induce bcl-2 down-regulation and
apoptosis in acute promyelocytic leukemia (APL) [18, 19] and
chronic B-cell leukemia [20] at nontoxic concentrations. The
inhibition of bcl-2 leads to the activation of the proteolytic
caspases, which regulate the further steps of cell death [21].
As2O3 has been used for APL treatment and led to complete
remission in 90% of the patients and prolonged survival
[19, 22]. SS patients have been treated systematically with
As2O3 with little success, as the As2O3 levels in the skin have not
been high enough [23].
In this study, we investigated the effects of As2O3 on the cell
survival/death genes bcl-2, bcl-xL, mcl-1, bax, bad and the
transcription factors NFkB and STAT5 by western blot and
electrophoretic mobility shift assays (EMSA) as well as
transcription factor enzyme-linked immunosorbent assays
(ELISAs), using nuclear and cytoplasmatic extracts from CTCL
cell lines Hut78 and MyLa 2059. We also investigated whether
As2O3 leads to cell death in CTCL cell lines in vitro and whether
As2O3 causes remission of human CTCL tumors in nude mice
in vivo.
material and methods
cells and cell culture
The cell line Hut78 (SS) was obtained from ECACC. The cell line MyLa
2059 (MF) was a kind gift of Dr Keld Kaltoft, University of Aarhus,
Denmark. Hut78 and MyLa cells were grown in Hepes-buffered RPMI-1640
medium supplemented with 2 mM glutamine, 10% fetal calf serum,
0.25 mg/ml amphotericin B, 100 U penicillin G, 100 U streptomycin and
1 mM pyruvate (all from Invitrogen, Basel, Switzerland).
induction of apoptosis
Apoptosis was assessed in vitro after growing 2 · 105 Hut78 or MyLa 2059
cells in the presence of 0.5–2 lM As2O3 for 10–14 days, depending on the
sensitivity of the tested cell line to the corresponding agent. Cell death was
monitored by observation of cell morphology, cell counting and trypan
blue staining as well as MTT assays and flow cytometric analysis of Annexin
V/7-amino-actinomycin-D (AAD)-stained cells as further described below.
Fresh MF and SS cells from patients were not analyzed, as they survive
only a shot time in culture and do not propagate.
MTT assay
Cells were cultured in the presence of various concentrations
of As2O3 for 3 days. Cells were thereafter washed and
resuspended in DMEM containing 0.5 mg/ml MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
(Sigma, Buchs, Switzerland) and incubated for 3 h at 37C.
Cells were then washed and the converted dye solubilized with
1 ml acidic isopropanol (0.04 M HCl in absolute isopropanol).
The absorbance of the converted dye was subsequently
measured at a wavelength of 570 nm.
flow cytometry
As2O3-treated cell suspensions were stained with Annexin V-PE
and 7-AAD following the manufacturer’s guidelines and
analyzed on a FACScalibur machine (both BD Biosciences,
Switzerland). Annexin V-PE positive, 7-AAD negative cells
were considered early apoptotic and cells that were in late
apoptosis or already dead were both Annexin V-PE and 7-AAD
positive.
western blotting
The antibodies against bcl-2 (sc-1041), bcl-x (sc-1041), mcl-1
(sc-819) and beta actin (sc-1616) were from Santa Cruz
Biotechnology Inc. For western blotting, 30 lg of protein of
cytoplasmatic extracts were run on a 9% sodium dodecyl
sulfate polyacrylamide gel and separated by polyacrylamide gel
electrophoresis. The proteins were transferred to
a nitrocellulose filter using a Mini Trans Blot Cell (BioRad,
Reinach, Switzerland) following the manufacturer’s guidelines.
Unspecific antibody-binding sites were blocked by incubating
the membrane overnight at 4C in 2% milk in tris-buffered
saline (TBS), pH 8.0 containing 0.3% Tween 20 (TBS-T). The
membrane was then incubated with the corresponding first
antibody (1:1000 dilution) for 4 h at room temperature in 1%
milk in TBS-T. The incubation with the secondary antibody
(anti-rabbit, Santa Cruz Biotechnology Inc., 1:1000 dilution)
was done in TBS-T for 4 h at room temperature. The signal was
detected by incubating the membrane with BM purple AP
substrate (Roche Biochemicals, Rotkreuz, Switzerland)
following the manufacturer’s instructions.
nuclear and cytoplasmatic cell extracts
Extracts were prepared by the following method. Cells (1–2 ·
106) were swollen in 400 ll hypotonic buffer A (10 mM Hepes,
pH 7.9, 10 mM KCl, 1 mM benzamidine, 1 mM EGTA, pH
8, 1 mM EDTA, pH 8) for 20 min at 4C and thereafter passed
10 times through a 25-gauge needle. The suspensions were
then centrifuged at 16 000g for 30 s and the supernatants were
used as cytoplasmic extracts. The nuclear pellets were extracted
with 60 ll hypertonic buffer C (20 mM Hepes pH 7.9, 25%
glycerol 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA pH 8,
1 mM benzamidine). The supernatants were centrifuged for
5 min and then used as nuclear extracts for EMSAs.
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electrophoretic mobility shift assay
We carried out EMSAs with nuclear extracts of Hut78 and
MyLa 2059 cell lines as described earlier [24]. The nuclear
extracts were incubated with a radioactively labeled
oligonucleotide containing the binding sites for NFkB. We
compared nuclear extracts from untreated Hut78 and MyLa
2059 cells and Hut78 and MyLa 2059 cells which had been
treated with 1 lM (Hut 78 cells) or 2 lM As2O3 (MyLa 2059
cells) for 1, 2 and 4 days. The DNA–protein complexes were
analyzed on a nondenaturing 4% polyacrylamide gel. The
oligonucleotide for the DNA-binding site was synthesized by
Microsynth, Balgach, Switzerland.
transcription factor ELISA
We used the NFkB family transcription factor ELISA from
Active Motif, Rixenart, Belgium. A DNA oligonucleotide
containing the DNA-binding sequence of NFkB was attached to
the surface of a 96-well plate. After rehydration, the nuclear
extracts of the MF and SS cells were added and incubated for 1
h at room temperature to let the NFkB protein bind to their
DNA motif. The plates were then washed to remove unbound
proteins, and antibodies against the different proteins of the
NFkB family were added. After 1 h incubation at room
temperature, the first antibodies were washed away and
a second antibody coupled to horseradish peroxidase (HRP)
was added for 1 h at room temperature. The addition of the
HRP substrate to the well started a color reaction, which
allowed the measurement of the DNA-bound transcription
factor. The specificity of the DNA-binding reaction was
monitored by control experiments where oligonucleotides
containing the wild-type or mutated DNA-binding motif of
interest were added as competitors.
mice, tumor induction and As2O3 treatment
Athymic nude mice from Harlan, Oxon, UK were kept under
sterile conditions in the central animal laboratory of the
University Hospital Zurich; 3 · 106 MyLa 2059T cells were
injected s.c. into the right flank of the mice. Tumors were
visible after 2–3 weeks in 70%–80% of the mice. The tumor
sizes were measured by calipers and the volumes were
calculated by the formula V = (length · width · height)/2. The
MyLa 2059T cells were derived from a tumor induced in
athymic nude mice by standard MyLa 2059 cells. The cells were
examined for the presence of murine pathogens before
injection. The cells were injected s.c., since the skin of nude
mice is extremely thin (3–6 cell layers) and does not allow
intradermal injections. The tumors were injected with As2O3
directly, as the tail veins of mice are fragile and break down
after daily repeated injections.
As2O3 treatment (50 or 200 lM in sterile PBS) was started
when the tumors had reached a minimal volume of 100 mm3.
Using an insulin syringe, 50 ll of As2O3 were injected when
the tumor volume was <200 mm3 and 100 ll As2O3 were
injected when the tumor havolume was >200 mm3.
The experiments were carried out following the ethic
guidelines for animal experiments of the Swiss National Fund
and were approved by the Veterinary Authorities of the Kanton
of Zurich, Switzerland (license no. 163/2003).
results
As2O3 causes cell death of cutaneous T cell
lines in vitro
It has been shown that As2O3 concentrations of 1 lM cause
cell death of leukemia cells [20]. To investigate the effects of
As2O3 on the proliferation and viability of Hut78 and MyLa
2059 cells, cells were cultured in the presence of various As2O3
concentrations.
Microscopic inspection of cell cultures showed the presence
of both Hut78 and MyLa 2059 cells displaying the typical
features of apotosis such as cell shrinkage, membrane blebbing,
nuclear fragmentation and cellular debris in a dose-dependent
manner (data not shown). By determining the number of
viable cells using the trypan blue exclusion test, we found that
culturing the cells in the presence of 0.5–2 lM As2O3
significantly decreased the number of viable Hut78 and MyLa
2059 cells. Figure 1A shows that As2O3 induced cell death
of most of the Hut78 cells at 0.5 lM within 8 days; 1 and
2 lM As2O3 had a comparable effect within 6 and 3 days,
respectively. MyLa 2059 cells were more resistant against As2O3
(Figure 1B). In the presence of 1 lM As2O3, the number of
MyLa 2059 cells remained nearly constant.
We confirmed these results by performing MTT assays
which showed a dose-dependent decrease of viable Hut78 and
MyLa 2059 cells after treatment with various concentrations
of As2O3 for 3 days (Figure 2A).
Figure 1. Arsenic trioxide causes cell death of (A) Hut78 and (B) MyLa 2059 cells. The cells were treated with different As2O3 concentrations as indicated.
The number of cells (y-axis) is given in percent (100% = 2 · 105 cells). The time of treatment is indicated on the x-axis.
original article Annals of Oncology
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To study whether the observed decrease in growth was due to
necrosis or apoptosis, Hut78 and Myla 2059 cells were
cultured in the presence of various concentrations of As2O3 for
3 days and thereafter stained with Annexin V/7-AAD and
subsequently analyzed by flow cytometry. Results demonstrated
that both Hut78 and MyLa 2059 cells underwent apoptosis in a
dose-dependent manner. Flow cytometry showed that the cells
moved from viable (Annexin V-PE and 7-AAD negative) to
early (Annexin V-PE positive and 7-AAD negative) and finally
late apoptosis (Annexin V-PE and 7-AAD positive) as the
As2O3 concentration was increased (Figure 2B). These data
demonstrate that apoptosis is the main reason for As2O3-
induced cell death.
the influence of As2O3 on apoptosis-regulating
proteins in CTCL cell lines
MF and SS cells express the antiapoptotic proteins bcl-2, bcl-
xL, mcl-1 and the proapoptotic genes bad and bax [7]. To test
whether As2O3 influences the abundance of these proteins
during the induction of apoptosis, we analyzed their expression
levels while culturing Hut78 and MyLa 2059 cells in the
presence of 1 lM As2O3. Figure 3 shows that bcl-2 and mcl-1
were faster down-regulated in the presence of As2O3 than
the beta actin control in both Hut78 and MyLa 2059 cells. The
bcl-xL protein shows another kinetic since its levels
increased on day 2, but subsequently dropped down to levels
that are lower than those in untreated cells, indicating that
there may be a defence mechanism that protects cells from
low concentration and short time exposure to As2O3. The
proapoptotic gene bax behaved similar to the beta actin control
and showed only a weak decrease after prolonged As2O3
exposure, whereas bad was more strongly down-regulated. The
data shown are representative of three independent
experiments.
the influence of As2O3 on constitutive transcription
factor activities in MF and SS cells
MF and SS cells contain constitutive NFkB activities [13, 15]
that may protect them from apoptosis. When measuring the
binding of NFkB to its DNA-binding sequence using EMSAs,
we found that binding was strongly reduced after prolonged
Figure 2. As2O3 induces apoptosis in Hut78 and MyLa 2059 cells. To quantify the effect of As2O3 on cell viability and growth, (A) Hut78 and (B) MyLa
2059 cells were grown for 3 days in the presence of various concentrations of As2O3. Cell viability was thereafter assessed by MTT assays. To determine
whether As2O3-induced cell death was due to apoptosis, the two cell lines were cultured in the presence of various As2O3 concentrations for 3 days and
thereafter stained with Annexin V-PE and 7-amino-actinomycin-D (7-AAD).
Figure 3. The influence of prolonged arsenic trioxide treatment on the
expression of the apoptosis-regulating bcl-2, bcl-xL, mcl-1, bad and bax
genes and the beta actin control gene in (A) Hut78 and (B) MyLa 2059
cells. The tested gene is indicated on the right. Lane 1: untreated cells, lane
2: cell treated for 2 days, lane 3: cell treated for 3 days, lane 4: cell treated
for 4 days with 1 lM arsenic trioxide.
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As2O3 treatment at 1 lM. However, the DNA-binding activity
of the ubiquitous Oct-1 transcription factor remained nearly
unchanged (Figure 4).
To determine the effects of As2O3 on the DNA-binding
activities of the different members of the NFkB transcription
factor family, we carried out transcription factor ELISAs using
the corresponding antibodies. Since MF and SS cells have also
been found to contain constitutive STAT5a and STAT5b
activities that may also protect MF and SS cells from apoptosis,
we also included these two proteins in our analysis as well.
Figure 5 shows that As2O3 strongly reduced the DNA-binding
activities of all the seven tested transcription factors p50, p65
(RelA), p52, RelB, c-Rel, STAT5a and STAT5b.
the influence of As2O3 on tumor growth in
a mouse model for MF
A mouse model for MF has recently been established using the
MyLa 2059 cell line and athymic nude mice [25]. To study
whether As2O3 can also slow down tumor growth in vivo,
3 · 106 cells were injected into the flanks of athymic nude mice.
Once the tumors reached a size of 100 mm3 As2O3 treatment
was started. Since cells in a solid tumor are much more resistant
against antitumor agents, we started with the injection of
50 lM As2O3 into the center of the lesion. The dose was
increased to 100 ll once the tumors reached a size >200 mm3.
Tumors <800 mm3 were treated with a volume of 150 ll. In
control mice that were injected with PBS alone, the tumors
reached a maximal volume of 1000 mm3 within 17–20 days
after which they were killed (Figure 6A). The treatment with 50
lM As2O3 delayed the growth of the tumors in three mice and
caused a complete remission in one animal (Figure 6B). To
investigate if a higher As2O3 concentration would result in
a higher percentage of remissions, we treated a second group of
mice with 200 lM As2O3. This higher concentration turned out
to be much more effective and caused four complete remissions
within 22–40 days, one complete remission after 90 days and
delayed tumor growth in another animal (Figure 6C),
demonstrating a dose-dependent effect of As2O3 on in vivo
tumor growth. At both concentrations, we could often observe
the formation of an ulcer-like lesion in the skin adjacent to the
tumor which got smaller and finally disappeared as the tumor
volume decreased. There was no lasting visible scar formation
in the mouse skin after treatment (Figure 7B and C). No lasting
side effects of As2O3 on the surrounding skin or other tissues
and organs could be observed.
Tumors that showed partial remission of both series of
experiments were excised and underwent histological
investigation (Figure 7D). The greatest cell destruction was
observed in the center of the lesions where tissue was
Figure 4. Prolonged arsenic trioxide treatment reduces the binding of the
NFkB transcription factor to its recognition sequence in (A) Hut78 and
(B) MyLa 2059 cells. The DNA binding of the Oct-1 transcription factor
remains unchanged. Lane 1: untreated cells, lane 2: cell treated for 2 days,
lane 3: cell treated for 3 days, lane 4: cell treated for 4 days with 1 lM
arsenic trioxide.
Figure 5. Transcription factor enzyme-linked immunosorbent assays of
NFkB and signal transducer and activator of transcription proteins of
As2O3-treated and -untreated (A) Hut78 and (B) MyLa 2059 cells.
The As2O3 concentration is indicated by the x-axis and the relative amount
of specific DNA-binding protein (extinction at OD595) is indicated by
the y-axis.
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fragmented to acelluar debris. This area was surrounded by
dead cells with fragmented nuclei followed by cells in several
stages of apoptosis. Living cells could be detected in the
periphery of the tumors. Unfortunately, the unspecific
reactions of the antibodies with the cellular debris of the As2O3-
treated tumor lesions prevented the analysis of these lesions for
the expression of apoptosis-regulating genes by specific
antibodies. The tissue surrounding the tumor showed no
damage caused by As2O3 and no significant scarring could be
detected.
discussion
Here, we demonstrate that the treatment of MF skin tumors
with As2O3 may be feasible. Recent data of Michel et al. [23]
have shown that intravenous concentrations of 1–2 lM As2O3
are sufficient to kill malignant SS T cells in the blood but
had no effect on skin lesions, suggesting that the resulting
nanomolar As2O3 concentrations in the skin were too low. Our
findings that up to 200 lM were needed to achieve a complete
remission confirm this assumption. Fortunately, such high
concentrations were well tolerated by the surrounding tissues
when the As2O3 was injected into the tumor or its close vicinity.
There were no signs of significant scarring in the mouse
skin although we often observed a temporary formation of an
ulcer-like lesion in the skin surrounding the tumor.
Michel et al. [23] observed that As2O3-triggered apoptosis
induced the translocation of cytochrome c from the
mitochondria to the cytoplasm. Here, we demonstrate that
As2O3 down-regulates the antiapoptotic genes bcl-2, bcl-xL and
mcl-1 which counteract the release of cytochrome c from
mitochondria. The down-regulation of these genes is therefore
a good explanation for the observed translocation of
cytochrome c from the mitochondria. This mechanism would
be comparable to the one observed in anoxia-induced
apoptosis [26].
Figure 6. Growth of MyLa 2059 cells derived tumors on immune-
deficient athymic nude mice; 3 · 106 MyLa 2059T cells were injected s.c.
into nude mice and treatment was initiated once the tumors had reached
a volume of 100 mm3. Mice received daily intralesional injections of (A)
PBS, (B) 50 lM or (C) 200 lM As2O3. Day 0 represents the time point
when the tumors had reached a volume of 100 ll and when the
treatment was started. Mice were euthanized once the tumors reached
a volume of 1 ml (1000 mm3), according to the directions of the Swiss
Animal Protection Law.
Figure 7. Tumor regression during (A–C) arsenic trioxide treatment and (D) biopsy of a treated tumor. (A) Untreated tumor, (B) regression and formation
of a central necrotic area in an As2O3-treated tumor, (C) site after complete tumor regression, (D) biopsy of a treated tumor. Dead tumor tissue can be seen
on the left with fragmented nuclei and on the right living tumor tissue showing first signs of apoptosis (chromatin condensation).
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The proapoptotic bax gene was also somewhat down-
regulated by As2O3, but the concentration of the bad protein
remained nearly unaffected. Thus, in a sum the equilibrium
between antiapoptotic and proapoptotic proteins that is crucial
for the survival of the cell [27, 28] was clearly skipped to the
side of the proapoptotic proteins. The data of the annexin
V/7-AAD assay confirm that As2O3 induces cell death mainly
by apoptosis.
As2O3 also down-regulates the constitutive DNA-binding
activities of the transcription factors of the NFkB and STAT
gene families. Especially the STATs may be important for the
regulation of the bcl-2, bcl-xL and mcl-1 genes, since a STAT5-
binding site has been identified in the regulatory gene of the
bcl-2 gene [29]. Thus, the down-regulation of STAT5 and other
STATs should result in a reduced expression of the
antiapoptotic genes.
The relationship between NFkB and these antiapoptotic
genes in MF and SS is less clear, since the NFkB-regulated
antiapoptotic cIAP genes are not expressed in these cells (J.-Z.
Qin, C.-L. Zhang and U. Do¨bbeling, unpublished data),
although they possess constitutive NFkB activities. The
literature on the effect of NFkB on bcl-2 and related proteins is
contradictory. An NFkB-regulated gene that could be
important for cell survival of CTCL cells is FLIP which is an
important mediator of antiapoptotic signals and has been
shown to play a role in the pathogenesis of anaplastic large-cell
lymphoma by protecting cells from apotosis [30].
Taken together, our results show that the death of MF and SS
cells by As2O3 is caused by reduced expression levels of
antiapoptotic proteins, which are paralleled by the down-
regulation of STAT and NFkB transcription factors. The in vivo
tumor regression upon local As2O3 treatment demonstrates
that As2O3 could be a novel and effective approach in the
treatment of CTCL tumors.
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